Clinical Trial Update: Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) [Phase 2]

View source ↗

Summary

Phase 2 trial update on sunitinib scheduling in metastatic renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genitourinary Cancer
• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Genitourinary Cancer, Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-02-27